Abstract: Disclosed herein are CRISPR/Cas9-based gene activation systems that include a fusion protein of a Cas9 protein and a protein having histone acetyltransferase activity, and methods of using said systems.

Abstract: Disclosed herein are therapeutic applications of CRISPR/Cpf1-based genome editing.

Abstract: Disclosed herein are compositions of transcription activator-like effectors transcription factors and methods of using the compositions for inducing gene expression of mammalian genes.

Abstract: Disclosed herein are therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use.

Abstract: Exemplary layered double hydroxides (LDHs) may comprise a compound of formula Mg4-yAlXy(OH)2, wherein X is Mn+2, Cu+2, Zn+2, or Fe+2, and 0.01?y?1. Exemplary layered double hydroxide hydrogels (LDH-gels) may comprise a hydrogel and at least one LDH. Exemplary hydrogels may comprise polyethylene (glycol) diacrylate (PEGDA) or polyacrylamide (PAAm). Exemplary LDH-gels may comprise at least one LDH comprising a compound of formula Mg4-yAlXy(OH)2, wherein X is Mn+2, Cu+2, Zn+2, or Fe+2, and 0.01?y?1.

Abstract: The present disclosure describes, in part, compositions and methods for safeguarding plant immunity to pathogens in response to environmental changes.

Abstract: The present invention includes a method, kits, and assays for identifying a human subject as having an increased risk of developing an autoimmune disease, or a human subject with multiple sclerosis caused by elevated soluble Interleukin 7 receptor (sIL7R), by obtaining a biological sample and detecting or measuring in the biological sample an amount of a soluble Interleukin-7 receptor (sIL7R) and an amount of an RNA Helicase DDX39B, whereby a lower expression of DDX39B and a higher secretion of sIL7R identifies the subject from which the biological sample was obtained as having an increased risk of developing an autoimmune disease, when compared to a human subject not having an autoimmune disease. The present invention also includes a method of modifying a treating of subjects based on the lower expression of RNA Helicase DDX39B alone or in combination with an increase in sIL7R.

Abstract: The present disclosure describes systems and methods for wastewater treatment. In some embodiments, a system may include one or more of a pair of electrodes, a first membrane selectively permeable to a first wastewater nutrient, a second membrane selectively permeable to a second wastewater nutrient, and at least one spacing frame comprising a structural element, a gasket, and a flow channel. In some embodiments, the system may further include a septic tank.

Abstract: Multifunctional microelectronics fiber probes can be chronically implanted in tissue of awake-behaving animals for understanding brain-viscera communication. These fiber probes can be made using thermal drawing to make hundreds of meters of flexible fiber that incorporates features such as light sources, electrodes, thermal sensors, and microfluidic channels in a multilayered configuration. The fiber mechanics can be tuned for two distinct device layouts: (1) higher-modulus, flexible brain fibers for implantation into deep-brain; and (2) soft, compliant gut fibers for implantation into the small intestine. Brain fibers can modulate the deep-brain mesolimbic reward pathway. Gut fibers can perform peripheral optogenetic stimulation of vagal afferents from the intestine to stimulate brain reward neurons.

Abstract: The present disclosure provides, in part, modulators of prostate-specific G-protein receptor (OR51E2/PSGR) and methods of treating, preventing, and diagnosing prostate cancer using the same.

Abstract: Methods for treating and preventing pain are described. The methods include administering a therapeutically effective amount of a GPR37L1 ligand to a subject in need thereof. Also described herein are pharmaceutical compositions containing the GPR37L1 ligands.

Abstract: The present disclosure describes methods and systems for risk detection and intervention for neurodevelopmental disorders. The method includes assessment of risk level, guidance and treatment recommendations and strategies, and longitudinal monitoring of patients with neurodevelopmental disorders. The assessments and monitoring can be integrated into the patient's health care program and electronic health record (EHR).

Abstract: Plasmonics-active nanoprobes are provided for detection of target biomolecules including nucleic acids, proteins, and small molecules. The nucleic acids that can be detected include RNA, DNA, mRNA, microRNA, and small nucleotide polymorphisms (SNPs). The nanoproprobes can be used in vito in sensitive detection methods for diagnosis of diseases and disorders including cancer. Multiplexing can be performed using the nanoprobes such that multiple targets can be detected simultaneously in a single sample. The methods of use of the nanoprobes include detection by a visible color change. The nanoprobes can be used in vivo for treatment of undesireable cells in a subject.

Abstract: The invention is directed to bispecific molecules comprising an HIV-1 envelope targeting arm and an arm targeting an effector cell, compositions comprising these bispecific molecule and methods of use. In certain aspects, the bispecific molecules of the present invention can bind to two different targets or epitopes on two different cells within the first epitope is expressed on a different cell type than the second epitope, such that the bispecific molecules can bring the two cells together. In certain aspects, the bispecific molecules of the present invention can bind to two different cells, wherein the bispecific molecules comprises an arm with the binding specificity of A32, 7B2, CH27, CH28 or CH44.

Abstract: Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an active agent at a low dose. In some embodiments, methods, compositions, and kits for treating and/or preventing tissue damage in a subject are provided, including methods, compositions and kits that include an active agent at a low dose.

Abstract: A system and method are provided for creating magnetic resonance (MR) images with reduced motion artifacts from the MR data from which the images are produced. The method includes selecting a candidate image from a plurality of candidate images reconstructed from the MR data. The method also includes registering the candidate image to a reference image, comparing the candidate image to a consistency map, and, based on comparing the candidate image using the consistency map, selecting a blending algorithm. The method also includes generating a blended image using the blending algorithm and the candidate image and repeating these steps for each candidate image. The method also includes performing a Fourier aggregation to generate a combined image and displaying the combined image with reduced motion artifacts compared to the plurality of candidate images.

Abstract: Provided herein are compositions and methods for detection of N6-methyladenosine (m6A) in ribonucleic acid (RNA). The provided compositions include fusion proteins that can be used to edit RNA and detect m6A residues. Also provided are nucleic acids, vectors, constructs, host cells, and transgenic animals that encode or express such fusions proteins.

Abstract: The present disclosure is directed to methods of treating a steatosis- associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.

Abstract: The disclosure provides compounds that inhibit the invasion of host cells by intracellular pathogens. The disclosure also relates to use of such compounds in methods of treating and preventing periodontitis or a periodontitis-related condition or symptom.

Abstract: The present disclosure provides genetically modified flowering plants that produce seedless fruit and methods for making and cultivating such plants. The genetically modified flowering plants express a modified Auxin Response Factor 8A (ARF8A) or an ortholog thereof.